Genes in panel
STRs in panel
Prev Next
Regions in panel
Prev Next

BabyScreen+ newborn screening

Gene: KCNH2

Green List (high evidence)

KCNH2 (potassium voltage-gated channel subfamily H member 2)
EnsemblGeneIds (GRCh38): ENSG00000055118
EnsemblGeneIds (GRCh37): ENSG00000055118
OMIM: 152427, Gene2Phenotype
KCNH2 is in 9 panels

1 review

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Green List (high evidence)

Rated as 'strong actionability' in paediatric patients by ClinGen.

The mean age at presentation of LQTS is 14 years. Cardiac events may occur at any age, but are most common from the pre-teen years through the 20s. Cardiac events are often triggered by administration of a QT-prolonging drug or hypokalemia. It has been estimated that 50% or fewer of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. Of individuals who die of complications of LQTS, death is the first sign of the disorder in an estimated 10-15%.

In patients with LQTS with a resting QTc greater than 470ms, a beta blocker is recommended.

Implantation with an implantable cardioverter defibrillator (ICD) can be effective in reducing SCD in LQTS patients.

With all forms of LQTS, a degree of caution with sporting activity is recommended.

Because the risk of adverse events increases in patients with LQTS with prolongation of the QTc >500 ms, QT-prolonging medications and electrolyte depleting medications (e.g. diuretics) should not be used in patients with LQTS unless there is no suitable alternative. Episodes of torsades de pointes can be precipitated by exposure to a QT prolonging medication, or hypokalemia induced by diuretics or gastrointestinal illness.
Created: 29 Dec 2022, 10:49 p.m. | Last Modified: 29 Dec 2022, 10:49 p.m.
Panel Version: 0.1761

Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Phenotypes
Long QT syndrome 2, MIM# 613688

Details

Mode of Inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Sources
  • Expert Review Green
  • BabySeq Category B gene
Phenotypes
  • Long QT syndrome 2, MIM# 613688
Tags
cardiac treatable
OMIM
152427
Clinvar variants
Variants in KCNH2
Penetrance
None
Panels with this gene

History Filter Activity

28 Jul 2024, Gel status: 3

Set Phenotypes

Tommy Li (Murdoch Children's Research Institute)

Added phenotypes Long QT syndrome 2, MIM# 613688 for gene: KCNH2

1 Feb 2023, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: kcnh2 has been classified as Green List (High Evidence).

1 Feb 2023, Gel status: 2

Removed Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag for review was removed from gene: KCNH2.

29 Dec 2022, Gel status: 2

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: kcnh2 has been classified as Amber List (Moderate Evidence).

29 Dec 2022, Gel status: 2

Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Phenotypes for gene: KCNH2 were changed from Long QT syndrome-2 to Long QT syndrome 2, MIM# 613688

29 Dec 2022, Gel status: 2

Added Tag, Added Tag, Added Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag for review tag was added to gene: KCNH2. Tag cardiac tag was added to gene: KCNH2. Tag treatable tag was added to gene: KCNH2.

18 Sep 2022, Gel status: 2

Created, Added New Source, Set mode of inheritance, Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

gene: KCNH2 was added gene: KCNH2 was added to gNBS. Sources: Expert Review Amber,BabySeq Category B gene Mode of inheritance for gene: KCNH2 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted Phenotypes for gene: KCNH2 were set to Long QT syndrome-2